Treatment selection in castration-resistant prostate cancer
Podcast 2021025
Questions:
- Is there a specific patient group in which you prefer using chemotherapy instead of androgen receptor pathway inhibitors?
- Are there any clinical factors aiding the selection between abiraterone and enzalutamide?
- Should we refrain from abiraterone treatment in patients with diabetes?
- What should be the optimal treatment line for Lu-177 PSMA treatment in castration-resistant prostate cancer?
- Is there a role of immunotherapy in castration-resistant prostate cancer in current clinical practice?
Expert
/attachment.e-eso.net%2F48%2F2021063012341701.jpg)
National Cancer Institute - IRCCS Foundation
Milan, Italy
Milan, Italy
30
Sep 2021
